Change search
ReferencesLink to record
Permanent link

Direct link
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Show others and affiliations
2012 (English)In: Breast cancer research : BCR, ISSN 1465-542X, Vol. 14, no 3, R76- p.Article in journal (Refereed) Published
Abstract [en]

ABSTRACT: INTRODUCTION: Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use. METHODS: Within the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed. RESULTS: For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47 (1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5 kg/m2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25 (1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although this risk increase was weaker for ER-PR- disease (Phet = 0.035). The association of HRT was significantly stronger in the leaner women (BMI ≤22.5 kg/m2) than for more overweight women (BMI ≥25.9 kg/m2) for, both, ER-PR- (HR: 1.74 (1.15 to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime. CONCLUSIONS: An elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of hormone-receptor negative tumors.

Place, publisher, year, edition, pages
London: BioMed Central, 2012. Vol. 14, no 3, R76- p.
Keyword [en]
body-mass index, estrogen-receptor, united-states, postmenopausal women, premenopausal omen, physical-activity, fat distribution, nutrition, size, weight
National Category
Surgery Cancer and Oncology
URN: urn:nbn:se:umu:diva-57240DOI: 10.1186/bcr3186PubMedID: 22583394OAI: diva2:540564
Available from: 2012-07-10 Created: 2012-07-10 Last updated: 2012-12-19Bibliographically approved

Open Access in DiVA

Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status(402 kB)144 downloads
File information
File name FULLTEXT02.pdfFile size 402 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sund, MalinLenner, Per
By organisation
SurgeryCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 144 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 81 hits
ReferencesLink to record
Permanent link

Direct link